The 2026 AHA/ACC/ADA/ASN guideline updates and expands management strategies for cardiovascular-kidney-metabolic syndrome, targeting clinicians caring for affected patients.
- 39 cites
Moving in Circulation.
Rebuilt
The 2026 AHA/ACC/ADA/ASN guideline updates and expands management strategies for cardiovascular-kidney-metabolic syndrome, targeting clinicians caring for affected patients.
Newest first · last 60 days
Semaglutide reduces vascular resistance and prevents fibrosis in kidneys, supporting kidney function preservation in type 2 diabetes with chronic kidney disease.
Machine learning model achieved 87.77% ROC AUC, significantly enhancing variant prioritization in CKD within a small, imbalanced cohort.
Journals this month
Moving areas, week to 3 Oct 2026